MedTrace Logo

A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid

NCT04499235 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-09-14

Study results available
· View outcomes & findings →

Summary

This study will evaluate the therapeutic effect and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP).

Conditions

  • Pemphigoid, Bullous

Interventions

DRUG

Mometasone furoate

Topical mometasone furoate

DRUG

AKST4290

Oral AKST4290

DRUG

Placebo

Oral placebo

Sponsors & Collaborators

  • Alkahest, Inc.

    lead INDUSTRY

Principal Investigators

  • Alkahest Medical Monitor · Alkahest, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-30
Primary Completion
2021-03-29
Completion
2021-04-14

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04499235 on ClinicalTrials.gov